Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer
The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by National Cancer Institute (NCI).
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Kantonsspital Graubuenden
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00898794
First received: May 9, 2009
Last updated: NA
Last verified: February 2009
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the effect of bevacizumab and VEGF on platelet clustering.
PURPOSE: This research study is looking at the effect of bevacizumab and VEGF on platelet clustering in patients with cancer who are receiving bevacizumab.
| Condition | Intervention |
|---|---|
|
Unspecified Adult Solid Tumor, Protocol Specific Unspecified Childhood Solid Tumor, Protocol Specific |
Biological: bevacizumab Other: coagulation study Other: laboratory biomarker analysis Other: platelet aggregation test |
| Study Type: | Observational |
| Official Title: | Influence of Bevacizumab and VEGF on Platelet Aggregation |
Resource links provided by NLM:
Further study details as provided by National Cancer Institute (NCI):
Primary Outcome Measures:
- Influence of bevacizumab on platelet aggregation [ Designated as safety issue: No ]
- Influence of VEGF on platelet aggregation [ Designated as safety issue: No ]
- Influence of VEGF or bevacizumab on cyclooxygenesis [ Designated as safety issue: No ]
- Correlation between medication sequence and platelet aggregation [ Designated as safety issue: No ]
| Estimated Enrollment: | 20 |
| Study Start Date: | October 2007 |
| Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- To determine the influence of bevacizumab on platelet aggregation in patients receiving bevacizumab for cancer.
- To determine the influence of VEGF on platelet aggregation.
- To determine the influence of VEGF or bevacizumab on cyclooxygenesis.
- To determine if the sequence of medication plays a role in platelet aggregation.
OUTLINE: Blood samples are collected before and after bevacizumab infusion. Samples are analyzed for measurements of platelet aggregation, coagulation parameters, and endothelial activation (e.g., fibrin fragment F1 and 2, thrombin and antithrombin complex, soluble P-selectin, Von Willebrand factor and factor VIII, tissue factor, and endothelin 1).
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
DISEASE CHARACTERISTICS:
- Receiving bevacizumab for cancer
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00898794
Locations
| Switzerland | |
| Kantonsspital Graubuenden | Recruiting |
| Chur, Switzerland, CH-7000 | |
| Contact: Roger von Moos, MD 41-81-256-6646 roger.vonmoos@ksgr.ch | |
Sponsors and Collaborators
Kantonsspital Graubuenden
Investigators
| Principal Investigator: | Roger von Moos, MD | Kantonsspital Graubuenden |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00898794 History of Changes |
| Other Study ID Numbers: | CDR0000631252, KSGR-GR-01/07 |
| Study First Received: | May 9, 2009 |
| Last Updated: | May 9, 2009 |
| Health Authority: | Unspecified |
Keywords provided by National Cancer Institute (NCI):
|
unspecified adult solid tumor, protocol specific unspecified childhood solid tumor, protocol specific |
Additional relevant MeSH terms:
|
Neoplasms Bevacizumab Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances |
Physiological Effects of Drugs Pharmacologic Actions Growth Inhibitors Antineoplastic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013